LINK TO ENTIRE NEWS RELEASE
NanoViricides, Inc. Achieves Broad Success in Initial FluCide-I(TM) Anti-Influenza Studies
Monday March 20, 7:30 am ET
Company Says That Nanoviricides(TM) is Now a Proven Platform To Attack Bird Flu
WEST HAVEN, Conn.--(BUSINESS WIRE)--March 20, 2006--NanoViricides, Inc. (Pink Sheets:NNVC - News), today announced it has received additional results from its FluCide-I(TM) efficacy studies performed at a major US research facility. On the basis of these data, Dr. Krishna Menon, the Company's Chief Regulatory Officer, said that the drug candidate tested was worthy of filing an Investigational New Drug Application (INDA) with the FDA. "The results were so positive that with an appropriate dosage protocol, it may be possible to save human lives even in bird flu cases using this test nanoviricide itself," suggested Dr. Menon.